Joop H Jansen (J H Jansen)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Topics

Cell Proliferation

Top Venues

Cancer immunology, immunotherapy : CII

Cellular and molecular life sciences : CMLS

This page only lists publications with an associated author ORCID identifier.

Publications

Priscilla Kamphuis, Isabelle A van Zeventer, Aniek O de Graaf, Giulio Genovese, Jonas B Salzbrunn, Avinash G Dinmohamed, Bert A van der Reijden, Jan Jacob Schuringa, Joop H Jansen, Gerwin A Huls
Clonal Hematopoiesis Defined by Somatic Mutations Infrequently Co-occurs With Mosaic Loss of the Y Chromosome in a Population-based Cohort. HemaSphere 7 (10) (2023)
Jesper van Eck van der Sluijs, Diede van Ens, Jolanda Brummelman, Daan Heister, Aastha Sareen, Lisa Truijen, Dorette S van Ingen Schenau, Mirjam H M Heemskerk, Marieke Griffioen, Michel G D Kester, Nicolaas P M Schaap, Joop H Jansen, Anniek B van der Waart, Harry Dolstra, Willemijn Hobo
Human CD34 + -derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8 + T cell and NK cell responses in vitro and in vivo. Cellular and molecular life sciences : CMLS 80 (10) (2023)
Jesper van Eck van der Sluijs, Diede van Ens, Soley Thordardottir, Denise Vodegel, Inge A T Hermens, Anniek B van der Waart, J H Frederik Falkenburg, Michel G D Kester, Iris de Rink, Mirjam H M Heemskerk, Jannie Borst, Nicolaas P M Schaap, Joop H Jansen, Yanling Xiao, Harry Dolstra, Willemijn Hobo
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer immunology, immunotherapy : CII 70 (11) (2021)
Jolien M R Van der Meer, Paul K J D de Jonge, Anniek B van der Waart, Alexander C Geerlings, Jurgen P Moonen, Jolanda Brummelman, Janne de Klein, Malou C Vermeulen, Ralph J A Maas, Nicolaas P M Schaap, J S Hoogstad-van Evert, Petronella B Ottevanger, Joop H Jansen, Willemijn Hobo, Harry Dolstra
CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice. Oncoimmunology 10 (1) (2021)
Jolien M R Van der Meer, Ralph J A Maas, Karolin Guldevall, K Klarenaar, P K J D de Jonge, J S Hoogstad-van Evert, Anniek B van der Waart, J Cany, J T Safrit, J H Lee, E Wagena, Peter Friedl, Björn Önfelt, Leon F A G Massuger, Nicolaas P M Schaap, Joop H Jansen, Willemijn Hobo, Harry Dolstra
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer immunology, immunotherapy : CII 70 (5) (2020)
Charlotte M Mousset, Willemijn Hobo, Aafke de Ligt, Sjoerd Baardman, Nicolaas P M Schaap, Joop H Jansen, Anniek B van der Waart, Harry Dolstra
Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. Cancer immunology, immunotherapy : CII 69 (11) (2020)
Ralph J A Maas, J S Hoogstad-van Evert, Jolien M R Van der Meer, Vera Mekers, Somayeh Rezaeifard, Alan J Korman, Paul K J D de Jonge, Jeannette Cany, Rob Woestenenk, Nicolaas P M Schaap, Leon F Massuger, Joop H Jansen, Willemijn Hobo, Harry Dolstra
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology 9 (1) (2020)
Charlotte M Mousset, Willemijn Hobo, Yun Ji, Hanny Fredrix, Valeria De Giorgi, Robert D Allison, Michel G D Kester, J H Frederik Falkenburg, Nicolaas P M Schaap, Joop H Jansen, Luca Gattinoni, Harry Dolstra, Anniek B van der Waart
Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. Oncoimmunology 7 (10) (2018)